Malaysia

Tuberculosis profile

Population 2017 32 million

Estimates of TB burden*, 2017

<table>
<thead>
<tr>
<th></th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality (excludes HIV+TB)</td>
<td>1.3 (1.1–1.4)</td>
<td>4 (3.5–4.5)</td>
</tr>
<tr>
<td>Mortality (HIV+TB only)</td>
<td>0.3 (0.22–0.38)</td>
<td>0.93 (0.69–1.2)</td>
</tr>
<tr>
<td>Incidence (includes HIV+TB)</td>
<td>29 (25–34)</td>
<td>93 (79–107)</td>
</tr>
<tr>
<td>Incidence (HIV+TB only)</td>
<td>1.8 (1.5–2.1)</td>
<td>5.7 (4.8–6.6)</td>
</tr>
<tr>
<td>Incidence (MDR/RR-TB)**</td>
<td>0.49 (0.37–0.63)</td>
<td>1.5 (1.2–2)</td>
</tr>
</tbody>
</table>

Estimated TB burden by age and sex (thousands)*, 2017

<table>
<thead>
<tr>
<th></th>
<th>0-14 years</th>
<th>&gt; 14 years</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females</td>
<td>2 (1.5–2.4)</td>
<td>9.2 (7–11)</td>
<td>11 (8.8–13)</td>
</tr>
<tr>
<td>Males</td>
<td>1.8 (1.4–2.2)</td>
<td>16 (13–20)</td>
<td>18 (14–22)</td>
</tr>
<tr>
<td>Total</td>
<td>3.8 (3.1–4.4)</td>
<td>26 (21–30)</td>
<td>29 (25–34)</td>
</tr>
</tbody>
</table>

TB case notifications, 2017

- % tested with rapid diagnostics at time of diagnosis
  - % with known HIV status 87%
  - % pulmonary 85%
  - % bacteriologically confirmed among pulmonary 74%

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2017 87% (75–100)

TB patients facing catastrophic total costs

TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.05 (0.04–0.06)

TB/HIV care in new and relapse TB patients, 2017

- % notified tested for rifampicin resistance 47%

Laboratory-confirmed cases

MDR/RR-TB: 352, XDR-TB: 1

Patients started on treatment ****

MDR/RR-TB: 97, XDR-TB: 0

Treatment success rate and cohort size

New and relapse cases registered in 2016 80% 25 005

Previously treated cases, excluding relapse, registered in 2016 50% 736

MDR/RR-TB cases started on second-line treatment in 2015 41% 85

XDR-TB cases started on second-line treatment in 2015 0

TB preventive treatment, 2017

% of HIV-positive people (newly enrolled in care) on preventive treatment 79%

% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 100% (87–100)

TB financing, 2018

National TB budget (US$ millions) 16

Funding source: 100% domestic, international, 0% unfunded

* Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

*** Includes cases with unknown previous TB treatment history

**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2019-09-09

Data: www.who.int/tb/data